FI122130B - Gamma-linoleenihappo- ja linolihappojäännöksiä sisältävän triglyseridiöljyn käyttö neurodegeneratiivisen sairauden hoidossa - Google Patents
Gamma-linoleenihappo- ja linolihappojäännöksiä sisältävän triglyseridiöljyn käyttö neurodegeneratiivisen sairauden hoidossa Download PDFInfo
- Publication number
- FI122130B FI122130B FI20051280A FI20051280A FI122130B FI 122130 B FI122130 B FI 122130B FI 20051280 A FI20051280 A FI 20051280A FI 20051280 A FI20051280 A FI 20051280A FI 122130 B FI122130 B FI 122130B
- Authority
- FI
- Finland
- Prior art keywords
- oil
- use according
- acid residues
- linolenic
- triglyceride
- Prior art date
Links
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title claims description 99
- 235000020664 gamma-linolenic acid Nutrition 0.000 title claims description 94
- 229960002733 gamolenic acid Drugs 0.000 title claims description 92
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 title claims description 91
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 title claims description 36
- 238000011282 treatment Methods 0.000 title claims description 34
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims description 23
- 230000004770 neurodegeneration Effects 0.000 title claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 title claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 29
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 235000020778 linoleic acid Nutrition 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 150000004665 fatty acids Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- 125000005313 fatty acid group Chemical group 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 240000004355 Borago officinalis Species 0.000 claims description 6
- 235000007689 Borago officinalis Nutrition 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 5
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000722877 Borago Species 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 3
- 230000003920 cognitive function Effects 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 150000002889 oleic acids Chemical class 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- VZCCETWTMQHEPK-YHTMAJSVSA-N (6e,9e,12e)-octadeca-6,9,12-trienoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\CCCCC(O)=O VZCCETWTMQHEPK-YHTMAJSVSA-N 0.000 claims 4
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 3
- 125000005457 triglyceride group Chemical group 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 239000003921 oil Substances 0.000 description 105
- 235000019198 oils Nutrition 0.000 description 105
- 201000002491 encephalomyelitis Diseases 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 235000021324 borage oil Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 235000008524 evening primrose extract Nutrition 0.000 description 11
- 244000025254 Cannabis sativa Species 0.000 description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 10
- 239000010475 evening primrose oil Substances 0.000 description 10
- 229940089020 evening primrose oil Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 10
- 208000016192 Demyelinating disease Diseases 0.000 description 8
- 206010012305 Demyelination Diseases 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 5
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 241000545744 Hirudinea Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 239000010473 blackcurrant seed oil Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- -1 lipid compounds Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 235000003130 Arctium lappa Nutrition 0.000 description 3
- 244000294263 Arctium minus Species 0.000 description 3
- 235000008078 Arctium minus Nutrition 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000498617 Mucor javanicus Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 241000219925 Oenothera Species 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 240000001890 Ribes hudsonianum Species 0.000 description 2
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241001125822 Trigla Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229940094199 black currant oil Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- KOBUHTMAMVEYSR-IUPFWZBJSA-N 1,3-bis[(15z)-tetracos-15-enoyloxy]propan-2-yl (15z)-tetracos-15-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC KOBUHTMAMVEYSR-IUPFWZBJSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241001166076 Diapheromera femorata Species 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 235000007849 Lepidium sativum Nutrition 0.000 description 1
- 244000211187 Lepidium sativum Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010048393 Multiple sclerosis relapse Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 235000011483 Ribes Nutrition 0.000 description 1
- 241000220483 Ribes Species 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000016911 Ribes sativum Nutrition 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 235000016897 Ribes triste Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000010598 long-chain omega-6 fatty acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 231100000052 myelotoxic Toxicity 0.000 description 1
- 230000002556 myelotoxic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940081852 trilinolein Drugs 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0311081.4A GB0311081D0 (en) | 2003-05-14 | 2003-05-14 | Treatment of neurodegenerative conditions |
| GB0311081 | 2003-05-14 | ||
| US49733203P | 2003-08-25 | 2003-08-25 | |
| US49733203 | 2003-08-25 | ||
| PCT/GB2004/002089 WO2004100943A1 (en) | 2003-05-14 | 2004-05-14 | Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease |
| GB2004002089 | 2004-05-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20051280A0 FI20051280A0 (fi) | 2005-12-13 |
| FI20051280A FI20051280A (fi) | 2006-02-07 |
| FI122130B true FI122130B (fi) | 2011-09-15 |
Family
ID=9958058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20051280A FI122130B (fi) | 2003-05-14 | 2005-12-13 | Gamma-linoleenihappo- ja linolihappojäännöksiä sisältävän triglyseridiöljyn käyttö neurodegeneratiivisen sairauden hoidossa |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7935729B2 (ja) |
| EP (2) | EP1631280A1 (ja) |
| JP (2) | JP2006528233A (ja) |
| CN (2) | CN1901898A (ja) |
| AU (1) | AU2004237936B2 (ja) |
| CA (1) | CA2524036C (ja) |
| CH (1) | CH699430B1 (ja) |
| DE (1) | DE112004000762T5 (ja) |
| ES (1) | ES2294914B2 (ja) |
| FI (1) | FI122130B (ja) |
| GB (2) | GB0311081D0 (ja) |
| IS (1) | IS8083A (ja) |
| NO (1) | NO20055937L (ja) |
| SE (1) | SE531985C2 (ja) |
| WO (1) | WO2004100943A1 (ja) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| GB2442164B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| WO2005018632A1 (en) * | 2003-08-18 | 2005-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
| GB2442161B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Triglycerides |
| GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| WO2014160989A2 (en) | 2013-03-28 | 2014-10-02 | The Trustees Of Columbia University In The City Of New York | Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| EP2144618B1 (en) | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
| US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| US20110086914A1 (en) * | 2009-10-13 | 2011-04-14 | Bailes Julian E | Methods for Treating Traumatic Brain Injury |
| US9255720B2 (en) | 2010-04-21 | 2016-02-09 | Honeywell International Inc. | Demand control ventilation system with commissioning and checkout sequence control |
| US9500382B2 (en) | 2010-04-21 | 2016-11-22 | Honeywell International Inc. | Automatic calibration of a demand control ventilation system |
| US8918218B2 (en) | 2010-04-21 | 2014-12-23 | Honeywell International Inc. | Demand control ventilation system with remote monitoring |
| EP2409695B1 (en) | 2010-07-05 | 2018-03-21 | Beth Israel Deaconess Medical Center, Inc. | Sn-2-monoacylglycerols and lipid malabsorption |
| US8719720B2 (en) | 2010-09-24 | 2014-05-06 | Honeywell International Inc. | Economizer controller plug and play system recognition with automatic user interface population |
| US20140044827A1 (en) | 2012-08-10 | 2014-02-13 | Bodygenex LLC | Dietary supplement containing lyophilized dairy and linolenic acid |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| EP3027063B1 (en) | 2013-08-01 | 2018-11-21 | Bunge Loders Croklaan B.V. | Opo glyceride composition |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| US10060642B2 (en) | 2014-10-22 | 2018-08-28 | Honeywell International Inc. | Damper fault detection |
| US9845963B2 (en) | 2014-10-31 | 2017-12-19 | Honeywell International Inc. | Economizer having damper modulation |
| WO2016128830A1 (en) | 2015-02-11 | 2016-08-18 | Aker Biomarine Antarctic As | Lipid extraction processes |
| KR102515207B1 (ko) | 2015-02-11 | 2023-03-29 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 조성물 |
| SI3762368T1 (sl) | 2018-03-08 | 2022-06-30 | Incyte Corporation | Aminopirazin diolne spojine kot zaviralci PI3K-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2077371A (en) | 1937-04-13 | Synthetic drx | ||
| US2077731A (en) * | 1935-09-24 | 1937-04-20 | Albert J Aaby | Chimney scraper |
| US2617791A (en) | 1949-09-15 | 1952-11-11 | Trojan Powder Co | Recovery of valuable products from pentaerythritol mother liquor |
| US3082228A (en) | 1959-12-18 | 1963-03-19 | Escambia Chem Corp | Method for producing monoesters of polyunsaturated fatty acids |
| US3158541A (en) | 1959-12-18 | 1964-11-24 | Escambia Chem Corp | Product for reduction of blood cholesterol concentration |
| IE32979B1 (en) | 1968-03-07 | 1974-02-06 | Unilever Ltd | Spreadable fats |
| US3671563A (en) | 1968-04-19 | 1972-06-20 | Smith Kline French Lab | Glycerol 3-(2,2,2-trichloroethyl) carbonate |
| US3558656A (en) | 1968-04-19 | 1971-01-26 | Smith Kline French Lab | Glycerol trichloroethyl carbonate and derivatives |
| US3676472A (en) | 1969-07-28 | 1972-07-11 | American Home Prod | Certain linoleic and linolenic acid ester fractions of vegetable oils and derivatives thereof |
| US3748348A (en) | 1970-07-27 | 1973-07-24 | Lever Brothers Ltd | Directed-interesterified glyceridic oils having a high linoleic acid content and process for their production |
| US3671557A (en) | 1970-09-17 | 1972-06-20 | Smith Kline French Lab | 1,2-diacylglycerol 3-(2,2,2-trichloroethyl) carbonates |
| GB1370021A (en) | 1971-03-25 | 1974-10-09 | Unilever Ltd | Process for preparing usaturated carboxylic acids |
| US3855254A (en) | 1972-03-31 | 1974-12-17 | Lever Brothers Ltd | Interesterification process |
| GB1506563A (en) | 1974-04-25 | 1978-04-05 | Williams J | Immunosuppressive agents |
| US4058594A (en) * | 1974-04-25 | 1977-11-15 | John Williams | Immuno-suppressive agents |
| US3988446A (en) | 1974-11-07 | 1976-10-26 | Abbott Laboratories | Glycerides with anti-inflammatory properties |
| US3972907A (en) | 1975-03-24 | 1976-08-03 | G. D. Searle & Co. | Anti-hyperlipidemic fatty acids and esters |
| US4048202A (en) | 1975-04-11 | 1977-09-13 | G. D. Searle & Co. | 3-O-Alkanoylglyceric acids |
| US4181670A (en) | 1978-12-11 | 1980-01-01 | G. D. Searle & Co. | Phenyl 5Z,8Z,11Z,14Z-eicosatetraenoate and congeners |
| DE3368377D1 (en) | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
| US4607052A (en) | 1983-04-15 | 1986-08-19 | Roussel-Uclaf | Triglycerides, dietetic and therapeutical applications and compositions containing them |
| US4701469A (en) | 1983-04-15 | 1987-10-20 | Roussel Uclaf | Triglycerides, process for therapeutical applications and compositions containing them |
| US4701468A (en) | 1983-04-15 | 1987-10-20 | Roussel-Uclaf | Oxidized triglycerides having therapeutic utility |
| GB8404463D0 (en) | 1984-02-21 | 1984-03-28 | Efamol Ltd | Microbiological production of essential fatty acids |
| US5077312A (en) | 1984-07-08 | 1991-12-31 | Oncogen | Biologically active lipids binding membrane receptors |
| GB2178752B (en) | 1985-07-12 | 1989-10-11 | Unilever Plc | Substitute milk fat |
| GB8524275D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US5151291A (en) | 1985-12-27 | 1992-09-29 | Nisshin Flour Milling Co., Ltd. | Glycerides of eicosapentaenoic acid, processes for preparing the same and oil and fat products containing the same |
| US5306730A (en) | 1986-02-03 | 1994-04-26 | Kabushiki Kaisha Yakult Honsha | Botulinum toxin neutralizer |
| US5227403A (en) | 1986-10-01 | 1993-07-13 | The Nisshin Oil Mills, Ltd. | Fats and oils having superior digestibility and absorptivity |
| US4867965A (en) | 1986-10-02 | 1989-09-19 | Revlon, Inc. | Fatty acid diesters |
| FR2617161B1 (fr) | 1987-06-29 | 1989-10-27 | Azar Robert | Nouveaux glycerides d'acide gras insature et leur procede d'obtention |
| US4832975A (en) | 1987-09-29 | 1989-05-23 | The Procter & Gamble Company | Tailored triglycerides having improved autoignition characteristics |
| US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
| GB9026648D0 (en) | 1990-12-07 | 1991-01-23 | Efamol Holdings | Nutrition |
| US5922345A (en) | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
| PH11992043811B1 (en) | 1991-01-24 | 2002-08-22 | Martek Corp | Arachidonic acid and methods for the production and use thereof |
| US5658767A (en) | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
| IT1247165B (it) | 1991-03-15 | 1994-12-12 | Fidia Spa | Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie. |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| US5674901A (en) | 1995-06-01 | 1997-10-07 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
| US5618955A (en) | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
| ES2136189T3 (es) | 1993-01-15 | 1999-11-16 | Abbott Lab | Lipidos estructurados. |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| GB9301629D0 (en) | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| JPH0741421A (ja) | 1993-05-28 | 1995-02-10 | Suntory Ltd | ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤 |
| US20050027004A1 (en) | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| US5663450A (en) | 1993-08-17 | 1997-09-02 | Cv Therapeutics | Macrophage lipid chemoattractant |
| EP0734723A4 (en) | 1993-12-29 | 2001-04-11 | Kowa Tekuno Sachi Co Ltd | THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS |
| JPH07309773A (ja) | 1994-05-16 | 1995-11-28 | Sagami Chem Res Center | アセチルコリン放出促進剤 |
| FR2722410B1 (fr) | 1994-07-15 | 1996-10-04 | Grinda Jean Robert | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique |
| JP3770628B2 (ja) | 1994-08-09 | 2006-04-26 | サントリー株式会社 | 遅延型アレルギー反応を介する医学的症状の予防及び改善剤 |
| NZ280017A (en) | 1994-09-21 | 1997-06-24 | Scotia Holdings Plc | Use of n-6 or n-3 series essential fatty acid (efa), and optionally an oestrogen, to make a medicament to treat or prevent hormone replacement therapy (hrt) associated breast pain in peri- or postmenopausal women; medicaments containing the efa and estrogen. |
| EP0711503A3 (en) | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
| US5990163A (en) | 1995-01-13 | 1999-11-23 | The Salk Institute For Biological Studies | Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor |
| DE19503993A1 (de) | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen |
| US6410078B1 (en) | 1995-04-28 | 2002-06-25 | Loders-Croklaan B.V. | Triglycerides, rich in polyunsaturated fatty acids |
| DE69633818T2 (de) | 1995-08-07 | 2005-12-08 | Suntory Ltd. | Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen |
| GB9519661D0 (en) | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| US5776913A (en) | 1995-10-10 | 1998-07-07 | Colgate Palmolive Company | Therapeutic diet for metabolic abnormalities found in animals with lymphoma |
| US6015798A (en) | 1995-10-10 | 2000-01-18 | Colgate Palmolive Company | Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| GB2328155B (en) | 1996-04-12 | 2000-08-02 | Peptide Technology Pty Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
| US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
| US6340485B1 (en) | 1996-06-03 | 2002-01-22 | Croda International Plc | Compositions and uses thereof |
| DE69720737T3 (de) | 1996-06-03 | 2007-06-14 | Croda International Plc, Goole | Pflanzliche ölzusammensetzungen |
| CA2259330C (en) | 1996-06-29 | 2003-03-18 | The Scottish Agricultural College | Improvement of male fertility with antioxidants and/or polyunsaturated fatty acids |
| GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
| KR100657642B1 (ko) | 1996-10-11 | 2006-12-19 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는 오일 |
| IL131126A (en) | 1997-02-21 | 2003-04-10 | Abbott Lab | Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof |
| US6080787A (en) | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
| US6201022B1 (en) | 1997-03-27 | 2001-03-13 | Myorx, Inc. | Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid |
| US5968809A (en) | 1997-04-11 | 1999-10-19 | Abbot Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
| US6432684B1 (en) | 1997-04-11 | 2002-08-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
| US6051754A (en) | 1997-04-11 | 2000-04-18 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
| US20020037876A1 (en) | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| FR2765482B1 (fr) | 1997-07-07 | 2000-12-08 | Oreal | Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| EP0919230A1 (en) | 1997-12-01 | 1999-06-02 | Societe Des Produits Nestle S.A. | NMIFA's as anti-inflammatory agents in superficial mammal tissues |
| AU765670B2 (en) | 1998-04-03 | 2003-09-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic endogenous cannabinoids analogues and uses thereof |
| US7101914B2 (en) | 1998-05-04 | 2006-09-05 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
| US6214372B1 (en) | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
| US6696584B2 (en) | 1998-05-04 | 2004-02-24 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
| BR9912745A (pt) | 1998-08-04 | 2001-11-06 | Cargill Inc | Promotores da desnaturase de ácido graxo de plantas |
| KR100325581B1 (ko) | 1998-08-07 | 2002-08-24 | 오우택 | 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물 |
| AU5561999A (en) | 1998-08-13 | 2000-03-06 | Wistar Institute, The | Methods for reducing atherosclerotic plaques |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| DE10029562A1 (de) | 1999-06-24 | 2001-03-01 | Strathmann Ag & Co | Lipophile Brennesselextrakte, Verfahren zu deren Herstellung und ihre Verwendung |
| DE19930030B4 (de) | 1999-06-30 | 2004-02-19 | Meduna Arzneimittel Gmbh | CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform |
| FR2797584B1 (fr) | 1999-08-16 | 2008-07-25 | Stephane Desjonqueres | Utilisation de lipides peroxydes dans le traitement ou la prevention des plaies et inflammations des muqueuses de la cavite buccale |
| JP3779505B2 (ja) | 1999-08-24 | 2006-05-31 | 花王株式会社 | 油脂組成物 |
| US6426367B1 (en) | 1999-09-09 | 2002-07-30 | Efa Sciences Llc | Methods for selectively occluding blood supplies to neoplasias |
| US6340705B1 (en) | 1999-09-10 | 2002-01-22 | Monsanto Technology, Llc | Use of α-linolenic acid metabolites for treatment or prevention of cancer |
| EP1088552B1 (en) | 1999-09-30 | 2006-04-19 | Loders Croklaan B.V. | Compositions containing pinolenic acid and its use a health component |
| GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
| US20010047036A1 (en) | 1999-12-17 | 2001-11-29 | Vanderhoof Jon A. | Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| EG22407A (en) | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| US6361806B1 (en) | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
| EP1129711B1 (en) | 2000-02-24 | 2004-01-28 | Unilever N.V. | Pinolenic acid against diabetes |
| DE60106026T2 (de) | 2000-06-23 | 2006-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2002047176A (ja) | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| FR2815227B1 (fr) | 2000-10-17 | 2003-04-11 | Schwartz Laboratoires Robert | Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels |
| NO310176B1 (no) | 2000-11-13 | 2001-06-05 | Wadlund As | Sammensetning for hud som inneholder kitosan-konjugert CLA og kitosankonjugert vitamin A eller et <beta>-cyklodekstrin-konjugertvitamin A samt fremgangsmåte for fremstilling og anvendelse avdenne |
| US6528040B1 (en) | 2001-01-18 | 2003-03-04 | Maurine Pearson | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic |
| US6864242B2 (en) | 2001-03-05 | 2005-03-08 | Stephen P. Ernest | Enteral formulation |
| WO2002096408A1 (en) | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
| DE60235303D1 (de) * | 2001-07-02 | 2010-03-25 | Suntory Holdings Ltd | Verfahren zur herstellung von fett mit triglyceridhaltiger hochungesättigter fettsäure |
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| EP1285590A1 (en) | 2001-08-08 | 2003-02-26 | Société des Produits Nestlé S.A. | Lipid blends |
| AU784852B2 (en) | 2001-08-10 | 2006-07-06 | Mars, Incorporated | Canine support diet |
| US20030032674A1 (en) | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| ITMI20012732A1 (it) | 2001-12-20 | 2003-06-20 | Health Pharma S R L | Integratore alimentare per neuropatici |
| AUPS082102A0 (en) | 2002-03-01 | 2002-03-21 | Women's And Children's Hospital | Therapeutic properties of oils |
| CN101072509A (zh) | 2002-03-08 | 2007-11-14 | 孟山都技术有限公司 | 炎症的治疗和预防 |
| US20040048926A1 (en) | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| CN100428932C (zh) | 2002-05-17 | 2008-10-29 | 日研化学株式会社 | TGF-α表达抑制剂 |
| US7335481B2 (en) | 2002-07-24 | 2008-02-26 | Christer Owman | Methods of identifying compounds that affect a fatty acid cell-surface receptor |
| US20040220081A1 (en) | 2002-10-30 | 2004-11-04 | Spherics, Inc. | Nanoparticulate bioactive agents |
| US7074418B2 (en) | 2002-11-18 | 2006-07-11 | Changaris David G | Conjugated fatty acid based emulsion and methods for preparing and using same |
| US20040229950A1 (en) | 2002-11-26 | 2004-11-18 | Vanderhoek Jack Y. | Method and composition with conjugated linoleic acid esters |
| US6841573B2 (en) | 2002-11-27 | 2005-01-11 | Molecular Nutrition | Use of arachidonic acid as a method of increasing skeletal muscle mass |
| US20040209953A1 (en) | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
| US20040208939A1 (en) | 2003-04-18 | 2004-10-21 | Barry Sears | Novel dietary compositions to reduce inflammation |
| GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| WO2005018632A1 (en) | 2003-08-18 | 2005-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
-
2003
- 2003-05-14 GB GBGB0311081.4A patent/GB0311081D0/en not_active Ceased
-
2004
- 2004-05-14 CN CNA2004800129820A patent/CN1901898A/zh active Pending
- 2004-05-14 CN CN2011103208135A patent/CN102512411A/zh active Pending
- 2004-05-14 JP JP2006530503A patent/JP2006528233A/ja active Pending
- 2004-05-14 GB GB0521395A patent/GB2415378B/en not_active Expired - Fee Related
- 2004-05-14 EP EP04733020A patent/EP1631280A1/en not_active Withdrawn
- 2004-05-14 WO PCT/GB2004/002089 patent/WO2004100943A1/en active IP Right Grant
- 2004-05-14 CH CH01806/05A patent/CH699430B1/de not_active IP Right Cessation
- 2004-05-14 US US10/555,757 patent/US7935729B2/en not_active Expired - Fee Related
- 2004-05-14 DE DE112004000762T patent/DE112004000762T5/de not_active Ceased
- 2004-05-14 EP EP10195799A patent/EP2311450A1/en not_active Withdrawn
- 2004-05-14 ES ES200550074A patent/ES2294914B2/es not_active Expired - Fee Related
- 2004-05-14 CA CA2524036A patent/CA2524036C/en not_active Expired - Lifetime
- 2004-05-14 AU AU2004237936A patent/AU2004237936B2/en not_active Ceased
-
2005
- 2005-10-21 IS IS8083A patent/IS8083A/is unknown
- 2005-11-10 SE SE0502484A patent/SE531985C2/sv not_active IP Right Cessation
- 2005-12-13 FI FI20051280A patent/FI122130B/fi not_active IP Right Cessation
- 2005-12-14 NO NO20055937A patent/NO20055937L/no not_active Application Discontinuation
-
2011
- 2011-03-10 JP JP2011053394A patent/JP2011144195A/ja active Pending
- 2011-04-06 US US13/064,647 patent/US20110184063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IS8083A (is) | 2005-10-21 |
| ES2294914B2 (es) | 2010-03-16 |
| US20080090908A1 (en) | 2008-04-17 |
| CH699430B1 (de) | 2010-03-15 |
| NO20055937L (no) | 2005-12-14 |
| AU2004237936B2 (en) | 2011-03-10 |
| JP2006528233A (ja) | 2006-12-14 |
| EP2311450A1 (en) | 2011-04-20 |
| WO2004100943A1 (en) | 2004-11-25 |
| ES2294914A1 (es) | 2008-04-01 |
| CA2524036A1 (en) | 2004-11-25 |
| GB0521395D0 (en) | 2005-11-30 |
| CN1901898A (zh) | 2007-01-24 |
| US7935729B2 (en) | 2011-05-03 |
| CA2524036C (en) | 2014-01-28 |
| CN102512411A (zh) | 2012-06-27 |
| FI20051280A (fi) | 2006-02-07 |
| GB2415378B (en) | 2006-08-02 |
| FI20051280A0 (fi) | 2005-12-13 |
| US20110184063A1 (en) | 2011-07-28 |
| SE531985C2 (sv) | 2009-09-22 |
| GB0311081D0 (en) | 2003-06-18 |
| JP2011144195A (ja) | 2011-07-28 |
| GB2415378A (en) | 2005-12-28 |
| EP1631280A1 (en) | 2006-03-08 |
| AU2004237936A1 (en) | 2004-11-25 |
| SE0502484L (sv) | 2006-01-16 |
| DE112004000762T5 (de) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI122130B (fi) | Gamma-linoleenihappo- ja linolihappojäännöksiä sisältävän triglyseridiöljyn käyttö neurodegeneratiivisen sairauden hoidossa | |
| de Souza et al. | A baru almond–enriched diet reduces abdominal adiposity and improves high-density lipoprotein concentrations: a randomized, placebo-controlled trial | |
| JP6307442B2 (ja) | 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法 | |
| US20110092592A1 (en) | Diagnosis and treatment of hepatic disorder | |
| EP3583849A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| WO2006017627A2 (en) | Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance | |
| WO2010038796A1 (ja) | Ｃ型肝炎治療剤 | |
| US20060058384A1 (en) | Treatment of IGA nephropathy with omega-3 fatty acids | |
| EP0524796A1 (en) | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS | |
| Tang et al. | Conjugated linoleic acid attenuates 2, 4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling | |
| EP2355812B1 (en) | Lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis | |
| JPH04290822A (ja) | アレルギー予防薬および食品 | |
| CN112107570A (zh) | 施用包含二十二碳五烯酸的组合物的方法 | |
| US9861605B2 (en) | Enriched injectable emulsion containing selected fatty acid triglycerides | |
| Nienaber et al. | n-3 long-chain PUFA promote antibacterial and inflammation-resolving effects in Mycobacterium tuberculosis-infected C3HeB/FeJ mice, dependent on fatty acid status | |
| Mahmoodi et al. | Supplementation with omega-3 plus vitamin E and zinc plus vitamin C on metabolic syndrome components in postmenopausal women with type 2 diabetes | |
| Kindernay et al. | Beneficial Effects of Polyphenol-Rich Food Oils in Cardiovascular Health and Disease | |
| Giriraja et al. | An open-label, multicenter, phase 2 study of a food enriched with docosahexaenoic acid in adults with sickle cell disease | |
| JP4852296B2 (ja) | 血管炎症候群予防・治療剤 | |
| US20120270849A1 (en) | Combinations of niacin, omega-3 and plant sterols/stanols for prevention cholesterol treatment | |
| Voutour | Moderate Ethanol and N-6/N-3 Diet Interactions on Lipid Profile and Liver Function in Mice | |
| Mirhafez et al. | Mitra Hariri, Azam Rezaie Farimani, Ali Movahedi, Ronika Danesh Naderan, Tannaz Jamialahmadi, Luis E. Simental-Mendía, and Amirhossein Sahebkar | |
| Murad et al. | Prevention is better than Cure: Apple and apricot | |
| Metzler | Andrea Forschner, MD Giesela Metzler, MD Gernot Rassner, MD Gerhard Fierlbeck, MD Tuebingen, Germany |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 122130 Country of ref document: FI |
|
| MM | Patent lapsed |